South Korea · Delayed Price · Currency is KRW ADBiotech Statistics
Total Valuation
ADBiotech has a market cap or net worth of KRW 67.78 billion. The enterprise value is 65.99 billion.
| Market Cap | 67.78B |
| Enterprise Value | 65.99B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ADBiotech has 26.95 million shares outstanding. The number of shares has increased by 55.08% in one year.
| Current Share Class | 26.95M |
| Shares Outstanding | 26.95M |
| Shares Change (YoY) | +55.08% |
| Shares Change (QoQ) | +33.43% |
| Owned by Insiders (%) | 6.80% |
| Owned by Institutions (%) | 6.55% |
| Float | 4.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.39 |
| PB Ratio | 2.49 |
| P/TBV Ratio | 2.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.55.
| Current Ratio | 1.12 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.89 |
| Interest Coverage | -1.68 |
Financial Efficiency
Return on equity (ROE) is -23.55% and return on invested capital (ROIC) is -20.37%.
| Return on Equity (ROE) | -23.55% |
| Return on Assets (ROA) | -7.20% |
| Return on Invested Capital (ROIC) | -20.37% |
| Return on Capital Employed (ROCE) | -13.95% |
| Weighted Average Cost of Capital (WACC) | 7.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.33 |
| Inventory Turnover | 3.29 |
Taxes
In the past 12 months, ADBiotech has paid 10 in taxes.
| Income Tax | 10 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.88% in the last 52 weeks. The beta is 0.23, so ADBiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -8.88% |
| 50-Day Moving Average | 2,169.82 |
| 200-Day Moving Average | 2,331.25 |
| Relative Strength Index (RSI) | 58.05 |
| Average Volume (20 Days) | 175,832 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ADBiotech had revenue of KRW 12.57 billion and -3.53 billion in losses. Loss per share was -207.77.
| Revenue | 12.57B |
| Gross Profit | 5.01B |
| Operating Income | -4.41B |
| Pretax Income | -3.55B |
| Net Income | -3.53B |
| EBITDA | -3.48B |
| EBIT | -4.41B |
| Loss Per Share | -207.77 |
Balance Sheet
The company has 15.65 billion in cash and 14.88 billion in debt, with a net cash position of 767.95 million or 28.50 per share.
| Cash & Cash Equivalents | 15.65B |
| Total Debt | 14.88B |
| Net Cash | 767.95M |
| Net Cash Per Share | 28.50 |
| Equity (Book Value) | 27.23B |
| Book Value Per Share | 1,315.69 |
| Working Capital | 2.74B |
Cash Flow
In the last 12 months, operating cash flow was -860.98 million and capital expenditures -15.81 billion, giving a free cash flow of -16.67 billion.
| Operating Cash Flow | -860.98M |
| Capital Expenditures | -15.81B |
| Depreciation & Amortization | 923.76M |
| Net Borrowing | 9.40B |
| Free Cash Flow | -16.67B |
| FCF Per Share | -618.67 |
Margins
Gross margin is 39.87%, with operating and profit margins of -35.09% and -28.07%.
| Gross Margin | 39.87% |
| Operating Margin | -35.09% |
| Pretax Margin | -28.25% |
| Profit Margin | -28.07% |
| EBITDA Margin | -27.67% |
| EBIT Margin | -35.09% |
| FCF Margin | n/a |
Dividends & Yields
ADBiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -55.08% |
| Shareholder Yield | -55.08% |
| Earnings Yield | -5.21% |
| FCF Yield | -24.60% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.
| Last Split Date | May 26, 2021 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
ADBiotech has an Altman Z-Score of 0.12 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.12 |
| Piotroski F-Score | 4 |